Both classifications continued to require a 20% blast requirement for AML with BCR:ABL1 fusion to prevent diagnostic intersection with the parent disease, chronic myeloid leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.